Petiq, Inc. Provides Earnings Guidance for the Second Quarter of 2023 and Reiterates Earnings Guidance for the Full Year 2023
May 09, 2023 at 09:09 pm
Share
PetIQ, Inc. provided earnings guidance for the second quarter of 2023 and reiterated earnings guidance for the full year 2023. For the quarter, the company expects net sales of $270 million to $280 million, an increase of approximately 9.0% compared to the prior year period based on the mid-point of the guidance.
For the year, the company reiterating net sales of $970 million to $1,030 million, an increase of approximately 9.0% compared to 2022 based on the mid-point of the guidance.
PetIQ, Inc. is a pet medication and wellness company, which provides veterinary products and services. The Company operates through two segments: Products and Services. Products segment manufactures and distributes pet medication and health and wellness products to major United States retail and e-commerce channels through more than 60,000 points of distribution. It is focused its offerings on value-branded products, and third-party branded products for dogs and cats, including pet Rx medications, OTC medications, and wellness products. Services segment provides a comprehensive suite of services at approximately 2,600 community clinic locations and wellness centers hosted at retailers across 39 states. The segmentâs services include diagnostic tests, vaccinations, prescription medications, microchipping, grooming and hygiene and wellness checks. The Rx pet medications products include flea and tick control, heartworm preventatives, arthritis, thyroid, and other specialty medications.
PETIQ, INC. 
